Influvac

Influenza virus vaccine, the active ingredient in Influvac, is a vaccine presented as an injectable suspension for intramuscular and subcutaneous use. It is intended to prevent seasonal influenza caused by influenza virus types A and B in individuals six months of age and older, reducing the risk of infection and related complications. GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac is a vaccine that targets the influenza virus family to provide prophylactic protection against seasonal flu. - Seasonal influenza (A): Induces protective antibodies that lower the incidence of influenza A infection. - Seasonal influenza (B): Generates immunity that reduces the risk of influenza B disease. - General seasonal influenza: Decreases overall flu‑related illness severity and complications across all age groups.

Common Side Effects: - Injection site pain: Mild to moderate discomfort at the injection site. - Redness or swelling: Localized erythema or edema around the injection area. - Low‑grade fever: Transient temperature rise within 24‑48 hours. - Headache: Mild headache occurring shortly after vaccination. - Myalgia: Muscle aches that resolve within a few days.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: Rare neurological disorder potentially linked to vaccination. - Seizures: Uncommon febrile seizures in susceptible individuals. - High fever: Persistent temperature above 39°C lasting more than 48 hours. - Severe allergic reaction: Angioedema or bronchospasm requiring emergency care.

Influvac should be administered with consideration of the following precautions. - Allergy screening: Avoid use in persons with known hypersensitivity to any vaccine component. - Acute illness: Postpone vaccination in individuals with moderate or severe febrile illness. - Pregnancy: Consult a healthcare professional; limited safety data are available. - Immunocompromised patients: May exhibit reduced immunogenic response; monitor effectiveness. - Age restriction: Not recommended for children younger than six months. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Vaccination with Influvac may be influenced by other medical products. Major Interactions (Avoid): - Live attenuated vaccines: Do not co‑administer within four weeks to prevent interference. - Immunoglobulins or blood products: May diminish vaccine‑induced immunity if given concurrently. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): May mask post‑vaccination fever. - Immunosuppressive therapy: Could reduce antibody response; assess timing. - Other inactivated vaccines: Generally safe together but monitor for additive local reactions.